Next Phase Newsletter

By Erika Wu, Business Development Manager, Global Tech Hubs, LSN

RESI JPM will take place at the Marriott Marquis in San Francisco during the JPM conference week. This conference provides a comprehensive in-person experience on January 14, where service providers can connect directly with early-stage life science and healthcare companies and investors. RESI offers a valuable opportunity for exhibitors, including CROs, CMOs, banks, and law and consultant firms to network with startups that are actively seeking partnerships for development and growth.

Eva Garland Consulting (EGC), a consultant firm specializing in grant proposal preparation and strategies was an exhibitor at RESI Boston. Review their shared insights in the video testimonial which highlights the unique networking opportunities and targeted connections that RESI offers.

RESI’s commitment to early-stage companies gives service providers a specialized platform to reach ideal clients in life sciences. CROs and CMOs have the chance to connect with preclinical therapeutics, labs with R&D space can meet startups in need of facilities, consultant firms provide strategy for grants, regulatory, as well as other areas, and life science-specific banks and law firms specializing in IP and term sheet negotiations can connect with founders seeking these services.

The RESI exhibition package includes a table for promotion and networking in the exhibit hall, along with prominent logo placement on the RESI website, program guide, and onsite signage. Exhibitors also receive complimentary registration to participate in the partnering platform and attend all conference events, maximizing their visibility and networking potential. Interested in reaching a broad audience of early-stage entrepreneurs at RESI JPM? Contact us at resi@lifesciencenation.com to learn more!

By Max Braht, Business Development Manager, LSN

Life Science Nation (LSN) announces enhancements to our Innovator’s Pitch Challenge (IPC) at RESI conferences, responding directly to your feedback for more presentation time.

New IPC Format

Participants will now enjoy a 6-minute presentation followed by a 7-minute Q&A session with sector-specific investor judges. Additionally, each company will have access to table and poster space (excluding RESI London) and a standard 3-day ticket for both in-person and virtual partnering. This extended format allows companies to provide a more comprehensive overview of their investment readiness and engage in deeper discussions with potential investors.

Upcoming Events

• RESI London 2024, December 4 (In-person); 5-6 (Virtual Partnering Only)
• RESI JPM 2025, January 14 (In-person); 15-16 (Virtual Partnering Only)

Join us for the Innovator’s Pitch Challenge at:

Due to limited pitch slots, we encourage you to apply early.

For questions or to apply, please reach out to our team at salescore@lifesciencenation.com. Don’t miss this opportunity to showcase your innovations and connect with potential investors!

By Faith Patenaude, Investor Research Analyst, LSN

The upcoming Redefining Early Stage Investments (RESI) Conference in London is shaping up to be a remarkable event for life science innovators worldwide. The conference will be taking place in-person on December 4 at 11 Cavendish Square, followed by virtual partnering on December 5-6. RESI London 2024 is set to connect ambitious life science start-ups with a diverse array of early-stage investors and strategic partners from across the globe.

Featured RESI London Investors

RESI’s reach goes well beyond the UK. While London-based investors like Delin Ventures, Boost Capital Partners, and Calculus Capital will be actively participating, RESI London 2024 will also welcome an extensive lineup of international firms, opening doors to far-reaching networks and growth opportunities.

European representation will be especially strong. In addition to local players, leading firms such as M Ventures from The Netherlands and CVX Ventures from Denmark will be present, providing crucial European connections for attending start-ups.

But the participation doesn’t stop at Europe. From the United States, esteemed investors like Optum Ventures and Lifespan Vision Ventures will take part in the event. Expanding beyond the Eastern Hemisphere, attendees can connect with firms such as Teijin Pharma from Japan, and Brandon Capital Partners from Australia, all of whom are eager to explore new partnerships with innovative life science start-ups.

RESI London 2024 offers an unparalleled chance to engage with a diverse and globally-minded group of investors. Interested in joining? Contact us at resi@lifesciencenation.com or click here to learn more.

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

A few weeks ago, Life Science Nation (LSN) headed to Yokohama to attend BioJapan 2024 from October 9-11, 2024. As one of the largest partnering conferences in Asia focused on the life sciences industry, this year’s event attracted over 18,000 attendees over the course of 3 days. For many years, BioJapan has served as a useful platform for LSN to expand its international network, including startups, investors/strategic partners, bioclusters, service providers, and more.

This year, LSN was invited by Life Science Incubation Council (LSIC) to join a seminar on “how life science startups in Japan can work together with global partners”. Founded in 2022, LSIC is a Japanese organization that has created a platform on which key players in the sector such as start-ups, VCs, pharmaceutical companies, medical device companies and government organizations can work together to develop innovative technology seeds, aiming towards commercialization of these technologies. LSN has signed an MOU with LSIC earlier this year to collaborate on initiatives to support the life sciences ecosystem in Japan.

The seminar took place on the last day of BioJapan, Friday, October 11, and featured the following panelists: Claire Jeong (Life Science Nation), Hélène Moore (BIOQuébec), Angela Kukula (MedCity), and Toru Seo (NewSight Tech Angels). The seminar presented an opportunity for each panelist to shed more light into their activities and their respective ecosystems, and to provide guidance on how Japanese companies can establish better relationships with international partners for expanding their business on an international scale.

▲ Shigehiro Asano (National Cerebral and Cardiovascular Center, Osaka), Claire Jeong (VP of Investor Research, Asia BD), Toru Seo (NewSight Tech Angels), Nao Yoshizawa (Life Science Incubation Council), Hélène Moore (BIOQuébec), Angela Kukula (MedCity), Tsuneaki Sakata (Osaka University / Biocommunity Kansai BiocK)

It was a great honor for LSN to share the panel with key industry experts and engage with more connections in Japan. LSN looks forward to continue providing a platform for life science and healthcare startups to connect with investors and strategic partners. Whether you are a startup seeking to identify more international investors and partners, or an investor seeking more international dealflow, please contact RESI@lifesciencenation.com if you are interested in learning more about how LSN can be helpful.

As with previous years, this year’s BioJapan was a very productive and well-executed event, and we look forward to returning next year!